加拿大COVID-19疫情期间危重先天性心脏病的产前诊断率持续提高:多中心研究
该多中心研究纳入加拿大安大略省和阿尔伯塔省所有三级胎儿心脏中心2016年1月1日至2022年3月31日预产期的危重先天性心脏病病例,比较COVID-19疫情前与疫情期间的产前诊断率及妊娠和出生后结局。总体产前诊断率为69.8%,疫情前组68.3% vs 疫情暴露组73.5%(P=0.03);调整省份、日历时间趋势、孕周、距离最近三级胎儿心脏服务距离及遗传学诊断后,产前诊断率持续增加,疫情期间较疫情前有增加趋势。
要点
- 危重先心病总体产前诊断率69.8%,疫情前68.3% vs 疫情暴露组73.5%(P=0.03)。
- 产科超声中位孕周疫情前20.1周 vs 疫情暴露组19.8周(P=0.07),无显著差异。
- 30天婴儿死亡率疫情前2.5% vs 疫情暴露组1.8%(P=0.44),无显著差异。
核心结论
- 尽管COVID-19疫情期间临床服务减少,加拿大两个最大省份的危重先心病产前诊断率在疫情期间继续增加;这些发现为资源有限情况下细化胎儿心脏病转诊指征的影响提供了 reassurance。
研究设计与样本
- 多中心研究,纳入加拿大安大略省和阿尔伯塔省所有三级胎儿心脏中心2016年1月1日至2022年3月31日预产期、需要或预计需要新生儿干预的危重先心病病例;按妊娠满18周在2020年3月1日之前(疫情前)或之后(疫情期间)分层;采用Cox比例风险模型评估产前诊断率。
诊断标准与关键数值
- 总体产前诊断1238/1774例(69.8%),疫情前组858/1257例(68.3%)vs 疫情暴露组380/517例(73.5%)(P=0.03)。
- 产科超声中位孕周疫情前20.1周(IQR 19.0-22.0)vs 疫情暴露组19.8周(IQR 19.1-21.3)(P=0.07)。
- 从产科超声到危重先心病诊断的中位时间疫情前1.2周(IQR 0.6-2.2)vs 疫情暴露组1.2周(IQR 0.6-2.2)(P=0.59)。
- 孕22周前产前诊断疫情前454/848例(53.5%)vs 疫情暴露组221/378例(58.5%)(P=0.11)。
临床应用与阅片要点
- 研究显示疫情期间危重先心病产前诊断率继续增加,作者认为这些发现为资源有限情况下细化胎儿心脏病转诊指征的影响提供了 reassurance。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Travel restrictions, reallocation of health resources and physical distancing during the coronavirus disease 2019 (COVID-19) pandemic caused extraordinary strain on healthcare systems. The overall impact of public health measures during COVID-19 on the prenatal diagnosis of congenital heart disease (CHD) has received limited attention. We sought to determine the rate of prenatal diagnosis and the pregnancy and postnatal outcomes of critical CHD prior to and during the COVID-19 pandemic.
METHODS: Cases of critical CHD with estimated due date between 1 January 2016 and 31 March 2022 that required or were expected to require neonatal intervention were identified from all tertiary fetal cardiac centers in Ontario and Alberta, Canada. Pregnancies were stratified based on reaching 18 weeks' gestation before (pre-COVID-19) or after 1 March 2020 (during COVID-19), as the latter group would require ultrasound scanning under COVID-19 pandemic restrictions. Outcomes included timing of critical CHD diagnosis (prenatal or postnatal), gestational age at prenatal diagnosis, pregnancy outcome and infant mortality at 30 days and 1 year after birth. The rate of prenatal diagnosis was assessed using Cox proportional hazard modeling with time-varying and time-invariant cofactors.
RESULTS: Prenatal diagnosis occurred in 1238/1774 (69.8%) cases of critical CHD overall, of which 858/1257 (68.3%) cases were in the pre-COVID-19 group and 380/517 (73.5%) cases were in the COVID-19 exposure group (P = 0.03). There was no difference between the pre-COVID-19 group and the COVID-19 exposure group in median gestational age at obstetric ultrasound (20.1 (interquartile range (IQR), 19.0-22.0) weeks vs 19.8 (IQR, 19.1-21.3) weeks; P = 0.07), median time from obstetric ultrasound to diagnosis of critical CHD (1.2 (IQR, 0.6-2.2) weeks vs 1.2 (IQR, 0.6-2.2) weeks; P = 0.59) and prenatal diagnosis < 22 weeks' gestation (454/848 (53.5%) vs 221/378 (58.5%); P = 0.11). Termination of pregnancy was more common in the COVID-19 exposure group (pre-COVID-19, 20.9% vs during COVID-19, 27.5%; P = 0.01). Infant mortality at 30 days (pre-COVID-19, 2.5% vs COVID-19, 1.8%; P = 0.44) and at 1 year after birth (pre-COVID-19, 8.9% vs COVID-19, 8.6%; P = 0.86) did not differ between eras. Once adjusted for province, trends in calendar time, week of gestation, distance to closest tertiary fetal cardiac service and genetic diagnosis, the rate of prenatal diagnosis of critical CHD continued to increase, with a trend towards an increased rate during the COVID-19 pandemic compared with the pre-COVID-19 era.
CONCLUSIONS: Despite the reduction in clinical services during the COVID-19 pandemic, the rate of prenatal diagnosis of critical CHD continued to increase during the pandemic in two of Canada's largest provinces. These findings provide reassurance regarding the impact of refined fetal cardiology referral indications for resource-limited scenarios. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Eckersley L, Lad M, Rose H, et al. Rate of prenatal diagnosis of critical congenital heart disease continued to improve despite COVID-19 pandemic: multicenter Canadian study. Ultrasound Obstet Gynecol. 2025. PMID: 40975049. doi:10.1002/uog.70028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。